



A With chronic kidney disease



B Without chronic kidney disease



Subgroups	With chronic kidney disease				Without chronic kidney disease			
	No./total No. (IR per 1,000 PY)		Hazard ratio — (95% CI)	Forest plot	No./total No. (IR per 1,000 PY)		Hazard ratio — (95% CI)	Forest plot
	SGLT2i	GLP-1RA	_ (95% CI)		SGLT2i	GLP-1RA	_ (33% 31)	
\ge								
< 65	16/493 (17.09)	24/493 (28.72)	0.60 (0.32-1.12)	⊢	31/9030 (1.48)	33/9030 (2.14)	0.65 (0.40-1.07)	⊢
≥65	26/749 (23.85)	35/749 (33.20)	0.71 (0.43-1.19)	⊢ ●	15/1956 (3.80)	13/1956 (4.24)	0.89 (0.42-1.88)	ı—•
Sex								
Male	23/754 (18.32)	40/754 (34.86)	0.53 (0.31-0.88)	⊢	18/6795 (1.14)	36/6795 (3.11)	0.34 (0.19-0.60)	⊢
Female	13/503 (15.42)	21/503 (27.43)	0.56 (0.28-1.13)	├	9/4197 (0.95)	11/4197 (1.58)	0.54 (0.22-1.31)	-
Cirrhosis								
Yes	11/373 (19.12)	14/373 (25.44)	0.75 (0.34-1.65)	⊢	11/4485 (1.15)	15/4485 (2.15)	0.51 (0.24-1.12)	⊢
No	33/881 (21.23)	41/881 (30.08)	0.72 (0.46-1.14)	⊢	19/6499 (1.21)	32/6499 (2.78)	0.41 (0.23-0.73)	⊢
nsulin use								
Yes	27/656 (27.22)	35/656 (35.65)	0.78 (0.47-1.29)	⊢	17/3926 (1.99)	26/3926 (3.99)	0.47 (0.25-0.86)	⊢
No	13/580 (12.88)	22/580 (24.68)	0.53 (0.26-1.05)	⊢	20/7065 (1.20)	21/7065 (1.75)	0.66 (0.36-1.23)	└
RAS inhibitor use								
Yes	46/1078 (26.42)	58/1078 (35.11)	0.76 (0.52-1.12)	⊢●	24/6598 (1.48)	40/6598 (3.40)	0.42 (0.25-0.70)	⊢ •
No	2/148 (7.61)	3/148 (13.42)	0.55 (0.09-3.30)	•	4/4395 (0.43)	7/4395 (1.03)	0.40 (0.12-1.38)	-
Proteinuria								
Yes	7/111 (46.39)	13/111 (87.63)	0.56 (0.22-1.41)	—	4/269 (6.49)	5/269 (12.70)	0.45 (0.12-1.71)	-
No	30/1127 (15.82)	43/1127 (24.74)	0.65 (0.41-1.03)	⊢	18/10668 (0.74)	42/10668 (2.33)	0.29 (0.17-0.51)	⊢-
				0.1 1.0	-			0.1 1.0